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Abstract The primary aim of this study is to explore the
extent to which registry data may fulfill the evidence require-
ments of cost-effectiveness analysis (CEA) studies evaluating
biologic therapies for the treatment of psoriatic arthritis (PsA),
where trial data are lacking or insufficient. In addition, the
paper aims to identify how future data collection in PsA reg-
istries might be better tailored to inform CEA research. A
review of the literature was performed to identify existing
registries containing PsA patients. Where possible, informa-
tion was extracted on the design and characteristics of the
registries. The registries were then appraised according to a
set of criteria that was formulated based on the methods cur-
rently used to model PsA in the CEA literature. A review of
the literature identified 21 potentially relevant registries from
around the world containing patients with PsA. There was
substantial variation regarding the extent to which the regis-
tries, as a whole, were useful for the purposes of CEA studies.
There were also notable disparities found in terms of the ac-
cessibility of the registries to researchers. The critical review
conducted in this study showed that all of the registries iden-
tified are potentially useful, at least in some degree, for the
purposes of informing CEA studies in PsA. However, no in-
dividual registry on its own was found to meet all of the
evidence requirements when considering how the disease
has been modeled previously.
Keywords Biologics . Cost-effectiveness . Decisionmodel .
Psoriatic arthritis . Registry data
Introduction
In recent years, an increasing number of biologic therapies
have been made available for the treatment of psoriatic arthri-
tis (PsA). Biologics are particularly effective at controlling the
symptoms of PsA and have been shown to delay disease pro-
gression in terms of joint erosion [1]. However, these treat-
ments are expensive, and within resource constrained systems,
their value for money has been assessed by health technology
assessment (HTA) agencies to determine whether they should
be approved for reimbursement in public health care systems
[2–4]. Many HTA agencies require robust evidence demon-
strating that a drug therapy is cost-effective, as well as clini-
cally effective, to receive a positive reimbursement decision
[5]. As a result, cost-effectiveness evidence has come to play a
prominent role in decisions regarding the approval of biologic
treatments in many settings. Unfortunately, the development
of robust cost-effectiveness evidence for PsA treatments has
often been hindered by deficiencies in the evidence base. The
short-term nature of many phase 3 trials in this area means that
assumptions regarding the long-term efficacy of biologics are
required to investigate the cost-effectiveness of biologic ther-
apies over the remaining lifetime of an average patient.
Consequently, this can impose additional uncertainty sur-
rounding the results and, ultimately, reduce confidence in a
decision to accept or reject a treatment for reimbursement.
Whilst HTA bodies may have appraised many of the bio-
logic drugs available, albeit with suboptimal evidence, they
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have faced a greater challenge in establishing an optimum
treatment sequence. Research has shown that switching be-
tween biologic therapies should be considered in patients
experiencing treatment failure either due to primary non-re-
sponse, secondary loss of efficacy or adverse events [6].
Unfortunately, the scope for evaluating alternative treatment
sequences in the context of a clinical trial is limited, given the
need to capture switches between multiple different treat-
ments, necessitating a longer follow-up period.
Real-world data collected for purposes of research, in par-
ticular registry data, has the potential to circumvent many of
the aforementioned issues associated with the use of trial evi-
dence to inform CEA studies of biologic drugs in PsA patients.
There are multiple registries, such as the British Society for
Rheumatology Biologics Registry (BSRBR) and a registry in
Denmark (DANBIO), that capture information on PsA patients
receiving a variety of treatments, including biologic and non-
biologic therapies. One of the main advantages of using evi-
dence from registries such as these is that they follow patients
for up to 15 years and over multiple lines of treatment [7].
The aims of this paper are twofold. It first aims to explore
the extent to which existing registry data can be used to inform
CEA studies involving biologic therapies for the treatment of
PsA. The second aim of the paper is to identify how data
collection in PsA registries might be improved to inform fu-
ture CEA research.
We start by identifying relevant literature pertaining to PsA
registry data and use this to establish a list of previous or
ongoing patient registries around the world. Next, we extract
information about the design and characteristics of the each of
the registries, including whether or not the registries employ
measures of disease activity that are relevant from a clinical
and economic perspective. The registries are then appraised
according to a set of criteria that was formulated based on the
methods currently used to model PsA in the CEA literature.
Finally, the findings are used to inform recommendations re-
garding the use and collection of data in PsA patient registries
for the purposes of CEA.
Methods
Identifying registries
Reflecting the anticipated difficulty in identifying registry
studies, we have used a pearl growing approach [8] to generate
a full list of registries containing PsA patients. The pearl in this
instance is a review of clinical registries in psoriatic arthritis
published in 2011 [7]. This is supplemented with focused
internet searches to identify registries without any associated
publications that may be reported in the gray literature (e.g.
policy documents or websites). Furthermore, expert clinical
opinion was sought to identify registries falling outside of
both the published and gray literature.
For the purposes of this study, we define registry data ac-
cording to the definition set out in a report commissioned by
the Agency for Healthcare Research and Quality (AHRQ) on
the development and evaluation of registry data on patient
outcomes [9]. This report defined a registry as Ban organized
system that uses observational study methods to collect uni-
form data (clinical and other) to evaluate specified outcomes
for a population defined by a particular disease, condition, or
exposure, and that serves one or more predetermined scientif-
ic, clinical, or policy purposes^. Thus, this definition covers a
broad range of study types, including registries for health care
products (e.g. post-marketing surveillance studies and single-
arm open-label trials), health services registries and disease or
condition specific registries.
Data extraction and critical appraisal
To determine which information might be useful from avail-
able registries, the following data was extracted, where avail-
able: population included in the registry (including PsA sub-
groups, duration of disease on entering database), number of
patients, setting (country), treatments received, follow-up du-
ration, timing of patient follow-up, patient numbers at each
follow-up, outcomes recorded (including QoL and costs) and
data availability (barriers to access, industry funding).
In addition, a series of questions were formulated (see Box
1). These were informed by challenges noted in previous ap-
plied papers and a recent consensus statement on cost-
effectiveness modeling in RA and PsA. Specifically, Madan
and colleagues defined six components that can be used to
describe existing cost-effectiveness models: initial response,
longer-term disease progression, mortality, quality-adjusted
life year estimation, resource use and the selection and inter-
pretation of data [10]. A subsequent study identified model
components—including long-term disease progression, the
duration of treatment effects, health care resource usage and
mortality—where registry data could play an important role in
resolving current deficiencies in the use of evidence [11]. We
sought to identify available and appropriate registry data ac-
cording to these components.
In terms of outcomes that were collected in each of the
registries, availability of data from each of the registries were
reviewed in terms of their ability to inform a model structure
similar to that recently developed as part of the appraisal pro-
cess of the National Institute for Health and Care Excellence
(NICE) [12]. This model structure, set out in Fig. 1, was as-
sumed to reflect best current practice in the methods used to
model PsA in the CEA literature. Here, initial response to
treatment is determined by the PsA Response Criteria
(PsARC) and the Psoriasis Area Severity Index (PASI).
Subsequent disease activity is modeled using the Health
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Assessment Questionnaire (HAQ) and PASI, where HAQ is
assumed to increase (worsen) without treatment, and PASI is
assumed to remain constant.
Results
Registries containing PsA patients
Identified registries are shown in Table 1 below, along with
the country in which they are founded. Twenty-one registries
were identified in total, pertaining to 18 different countries.
There was very little information that could be acquired for the
Czech, Icelandic and Turkish registries, and as such, these
registries are excluded from further discussions.
Data extraction
Table 2 shows which data are available in each of the registries
for the purposes of informing CEA studies in PsA patients. The
large majority of registries do not capture any treatment re-
sponse within 3 to 6 months of patients starting a new treat-
ment, the time horizon typically specified in PsA clinical trials
following BSR/BAD guidance [13, 14]. The Reuma and
PsoBEST registries were the only ones found to collect evi-
dence in keeping with the recommendations set out by Madan
and colleagues [11], i.e. PsARC and PASI75 collected
3 months after the initiation of treatment. A further two regis-
tries collect PASI75 response either at 6 months or beyond
(GISEA, SwePSA). The paucity of short-term data on treat-
ment effects may reflect the intended nature of the registries,
namely that they are not designed for the purposes of clinical
research but also for operational reasons, as well as cost restric-
tions on the collection of data. A further complication regard-
ing the estimation of treatment effects is that the patients may
not enter the registry until they are established on treatment.
The evidence pertaining to disease progression is stronger
than that for treatment response. Sixteen of the registries col-
lect data on disease progression. This allows patients to be
tracked over time to determine how their disease changes
whilst on treatment. A handful of studies were also found to
be of potential value for determining treatment response and
treatment effectiveness at various stages of the treatment se-
quence (ARTIS, NOR-DMARD, PsoBEST, ROB-FIN,
SSATG). However, despite many of the registries collecting
evidence over multiple lines of treatment, the lack of treatment
response data (within 3 months) may limit the capacity to
estimate the effect of subsequent lines of treatment.
Most of the registries identified were found to record details
of patients withdrawing from treatment, including the exact date
of withdrawal and the reason for withdrawal. Unfortunately, the
usefulness of the registry evidence cannot be determined for
estimating the effect of treatment withdrawal on disease progres-
sion, as this would rely on outcome measures (i.e. HAQ scores)
being collected when patients withdraw from treatment. Only
one registry—the HRBT—was explicitly identified as having
done this. A number of registries also contain death data or are
linked to a national death registry. These registries may poten-
tially be useful for modeling the relationship between disease
severity andmortality risk.With the exception of three registries,
the degree of reporting on health care resource use in patients
was poor. Two of the registries (ARAD and ARTIS) are linked
to datasets containing health care utilization, and one registry
(NOR-DMARD) contains visit data in addition to medications
prescribed.
Accessibility of PsA registries
Table 3 provides information pertaining to the accessibility of
the registry data. The process for accessing registry data is
vague for a number of the registries, and a number do not have
any associated website or contact details. The requirement to
pay an access fee may be a barrier for some analysts wanting
to utilize data from the registries. A number of registries are
not explicit about the financial requirements, whereas a small
number explicitly state that an access fee will be charged
(BSRBR, CORRONA and NOAR). This is usually tailored
to the applicants’ status (clinical, non-clinical, student).
Discussion
No individual registry on its own was found to address all
of the questions set out in Box 1, and there was substantial
variation regarding the extent to which the registries were
Box 1 Critical appraisal questions
Q1. Which outcomes, if any, are collected to determine whether or not an
initial treatment response (12/16 week) is achieved?
Q2. Which outcomes, if any, are collected to assess the effect of
treatments on the disease symptoms?
Q3. Was information on the timing of patient withdrawal collected?
Moreover, was the reason for patient withdrawal recorded?
Q4. Which outcomes, if any, are collected to assess long-term disease
progression, in terms of arthritis-related progression?
Q5. Were outcomes collected in way that would allow long-term disease
progression to be estimated (i.e. beyond the initial treatment period)?
Q6.Was the data collected in a way that would permit the estimated effect
of treatment withdrawal on disease progression (e.g. estimate any
potential rebound effect)?
Q7. Does the registry data include information on health care resource use
in patients? Alternatively, can the registry data be linked to external
data on health care resource use in patients?
Q8. Does the data permit analyses to model the relationship between
disease severity and mortality risk?
Q9. Does the data permit treatment response and treatment effectiveness
to be determined at various stages of the treatment sequence (i.e.
first-line treatment, second-line treatment etc.)?
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useful for addressing each of the questions. Overall, the
evidence pertaining to question 3 would appear to be
strong given that the majority of the registries were found
to collect the time-to-withdrawal from treatment in pa-
tients, as well as the reasons for withdrawal from treat-
ment. Similarly, with regard to question 4, the majority of
the registries collected at least one relevant outcome mea-
sure for assessing treatment effects. The fact that most of
the registries follow patients over a long time horizon sug-
gests that they would also be useful for estimating long-
term disease progression (question 5).
The usefulness of the registry evidence could not be deter-
mined in many cases for the remaining research questions.
With the exception of three registries, the degree of reporting
on health care resource use in patients was poor (question 7).
Likewise, there were only six registries reported as being po-
tentially useful for modeling the relationship between disease
severity and mortality risk (question 8). Finally, only one of
the registries would appear to be capable of estimating the
effect of treatment withdrawal on disease progression (ques-
tion 6).
The review has also shown that there are notable disparities
in the accessibility of the registries to researchers. Only seven
of the registries identified had some form of formal applica-
tion procedure in place for researchers to apply for data access,
and of those registries, three had financial requirements. For
nine of the remaining registries, the procedure for accessing
data is complicated by the fact that there are no websites avail-
able to the public providing relevant contact details or infor-
mation about the study protocol. Thus, the pool of registry
evidence that we can say for certain that would be both acces-
sible and useful for CEA research is limited, especially in the
light of the financial barriers in place.
Another important consideration regarding the usefulness of
registry evidence is the extent to which the data can be gener-
alized across settings and jurisdictions. It is well established in
the health economics literature that there are a number of key
aspects related to a decision problem that may vary across ju-
risdictions [15–17]. These aspects include, but are not limited
to, the appropriate health care interventions to be compared and
the relevant patient subgroups to be investigated.Moreover, it is
important to ensure that the evidence inputs selected are appro-
priate to the jurisdiction under investigation, e.g. appropriate
health care unit costs and resource use estimates that correspond
with the typical clinical practice. Consequently, these additional
factors may further constrain the usefulness of the available
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Fig. 1 Model schematic for PsA. Figure reproduced with permission fromRodgers M, Epstein D, Bojke L et al. Etanercept, infliximab and adalimumab
for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-329
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registry data depending upon the specific decision problem
under investigation.
In a similar manner, it is important to realize that current
outcome tools, used for modeling disease progression, may be
inadequate for this disease. The HAQ is a measure of function,
mainly in the upper limb, and was developed for use in rheu-
matoid arthritis [18]. PsA is a complex heterogeneous disease
which impacts joints in a less predictable manner—small joint
involvement is less frequent, and lower limb joints may pre-
dominate over upper limb joints [19]. Moreover, there are
other aspects of the condition that can impact upon function
and quality of life such as enthesitis, dactylitis and spondylitis.
Future studies that model outcomes should encompass these
considerations. An outcome tool that measures across these
domains, such as a generic quality of life outcome, is more
appropriate for this disease.
Limitations
It is important to acknowledge that the methodology used to
identify previous or on-going registries in this study is subject
to limitations. First, the definition of registry data employed in
this study, taken from a report commissioned by the Agency
for Healthcare Research and Quality, is a broad one that
covers a range of different types of observational study. This
definition presents an issue with regard to the practicality of
identifying all potentially relevant registries given that it in-
cludes potentially huge numbers of small cohort studies.
Related to the issue is the fact that, to the authors’ knowledge,
there is no methodology available for the identification and
selection of registry studies for CEA. This is largely driven by
the lack of well-defined research question(s) in registry stud-
ies, especially when compared to the process of reviewing
RCTevidence. This lack of research question is not conducive
to a search-strategy based on keyword terms. Instead, the au-
thors decided that a pearl growing approach would offer great-
er flexibility. It is important to emphasize that there may be
additional benefits associated with registry evidence beyond
those considered in this paper. For instance, registry data can
circumvent some of the problems relating to the generalizabil-
ity of evidence from clinical trials, which can occur as a result
of strict inclusion criteria, by recruiting more inclusive popu-
lations of patients [20].
Lessons for the future
There are a number of recommendations regarding the future
collection of data in PsA registries that can be made based
upon the findings in this review. Firstly, the timing of the data
collection in many of the registries was incompatible with the
requirements of the modeling techniques used in contempo-
rary CEA studies [11]. For future research, we recommend
Table 1 Identified registries
Full name Country
ARAD Australian Rheumatology Association Database Australia
ARTIS Antirheumatic Therapies in Sweden Sweden
ATTRA Czech National Registry Czech Republic
BIOBADA-BRASIL Brazilian Biologic Registry Brazil
BIOBADA-SER 2.0 Spanish Registry for adverse events of biological
therapies in rheumatic diseases
Spain
BSRBR British Society of Rheumatologists Biologics Register UK
CORRONA Consortium of rheumatology researchers of north America USA
DANBIO Danish Database for Biological Therapies Denmark
GISEA Italian Group for the Study of Early Arthritis Italy
HRBT Hellenic Registry of Biologic Therapies Greece
ICEBIO – Iceland
NOAR Norfolk Arthritis Registry UK
NOR-DMARD Norwegian Anti-rheumatic Drug Register Norway
PsART Psoriatic Arthritis Registry of Turkey Turkey
PsoBEST German Psoriasis Registry PsoBest Germany
Reuma Rheumatic Diseases Portuguese Register Portugal
ROB-FIN National Register of Biological treatment in Finland Finland
SCQM Swiss Clinical Quality Management in Rheumatic Diseases Switzerland
SSATG South Swedish Arthritis Treatment Group Sweden
SwePsA Swedish Early Psoriatic Arthritis Registry Sweden
UoT Psoriatic Arthritis – Canada
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Table 2 Data available from registries
Measure of
treatment
response at
3 months
Measure of disease
progression at 3 months
Measure of disease
progression beyond
3 months
Patient withdrawal from treatment Health care resource use
data
Mortality data Multi-stage
treatment
sequenceDate Reason Measure of
disease
progression
ARAD None None HAQ, EQ-5D, SF-36,
AQoL
✓ ✓ ⨯ ARAD can be linked to
Medicare Australia Data
ARAD can be linked to
National Death Index
✓
ARTIS None HAQ HAQ ✓ ✓ Unclear Identification number can
be linked to the National
Patient Register
Identification number can
be linked to Census
Data
✓
BIOBADA-BRASIL None None None ✓ ✓ ⨯ Unclear Unclear Unclear
BIOBADA-SER 2.0 None None None ✓ ✓ ⨯ Unclear Unclear Unclear
BSRBR None None HAQ, SF-36 ✓ ✓ Unclear Unclear Yes ✓
CORRONA None Unclear HAQ, EQ-5D Unclear Unclear Unclear Unclear Unclear Unclear
DANBIO None None HAQ ✓ ✓ Unclear Unclear Identification number can
be linked to National
Death Registry
✓
GISEA None None HAQ, EQ-5D ✓ ✓ Unclear Unclear Yes ✓
HRBT None None Modified HAQ for
physical function
✓ ✓ ✓ Unclear Unclear ✓
NOAR None None HAQ, SF-36 Unclear Unclear Unclear Unclear Unclear Unclear
NOR-DMARD ACR Modified HAQ,
SF-36
Modified HAQ, SF-36 ✓ ✓ Unclear Yes Unclear ✓
PsoBEST PASI75a HAQ, EQ-5D HAQ, EQ-5D ✓ Unclear Unclear Unclear Yes ✓
Reuma PsARC HAQ, SF-36 HAQ, SF-36 ✓ ✓ Unclear Unclear Unclear Unclear
ROB-FIN ACR HAQ HAQ ✓ ✓ Unclear Unclear Unclear ✓
SCQM None HAQ, SF-36, EQ-5D HAQ, SF-36, EQ-5D ✓ ✓ Unclear Unclear Unclear Unclear
SSATG None HAQ, EQ-5D HAQ, EQ-5D ✓ ✓ Unclear Unclear Unclear ✓
SwePsA None None HAQ, SF-36 Unclear Unclear Unclear Unclear Unclear ⨯
UoT Psoriatic Arthritis None None HAQ, SF-36 ✓ ✓ Unclear Unclear Unclear ✓
a PASI score collected from which PASI75 can be calculated C
lin
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that data collection should take place 3 months after the initi-
ation of a treatment in PsA patients. In addition, the collection
of outcome measures in patients when they withdraw from
treatment would permit researchers to obtain empirically de-
rived estimates of disease progression, rather than having to
rely upon assumptions.
A second issue relates to the selection of variables. Only a
small number of registries are currently collecting the optimal
outcomes for estimating the initial response to treatment. To
this end, future data collection should ideally include PsARC,
PASI75 and HAQ outcome measures. Furthermore, there
were very few cases where registries could be identified as
having collected information relating to patient mortality or
health care resource use. Data collection pertaining to each of
these facets would greatly enhance the robustness of the evi-
dence used in future studies investigating the cost-
effectiveness of PsA treatments.
Finally, with regard to the generalizability of evidence
across jurisdictions, there are lessons that can be learned
from data registries established in other disease areas. For
example, the MDS-RIGHT database was established to
monitor outcomes in patients with myelodysplastic syn-
dromes across 17 countries using the same study protocol
[21]. The advantage of this approach is that it allows re-
searchers to account for variations occurring in clinical
practice across countries.
Conclusions
In recent years, there has been increased enthusiasm amongst
the health research community around the opportunities that
may be afforded by registry data for the evaluation of health
care interventions [22, 23]. The objective of this paper was to
understand these opportunities in the context of cost-
effectiveness modeling for PsA treatments. A review of the
literature identified 21 potentially relevant registries from
around the world containing patients with PsA. Most of the
registries identified were shown to be at least partly useful in
informing the evidence requirements as specified in previous
modeling efforts in this area. Overall, however, the registries
were generally lacking in evidence pertaining to the estima-
tion of initial treatment responses, disease progression follow-
ing withdrawal from treatment and the optimum sequences of
treatments for PsA.Moreover, there were a number of cases in
which the review was unable to determine the usefulness of
the registry data; namely, the collection of information about
health care resource use and patient mortality, as well as data
accessibility. It is hoped that the findings of this study will
provide the research community with a greater understanding
of the current opportunities available with regard to the appli-
cation of existing PsA registries for CEA. Furthermore, it is
hoped that the recommendations provided will inform future
data collection within a registry setting.
Table 3 Accessibility of PsA registries
Application process Financial require-ments Website
ARAD Application via website – https://arad.org.au/
ARTIS – – –
ATTRA – – http://attra.registry.cz/
BIOBADA-BRASIL – – https://biobadaser.ser.es/biobadamerica/Brasil/index.html
BIOBADA-SER 2.0 – – https://biobadaser.ser.es
BSRBR Application via website Yes http://www.rheumatology.org.uk/resources/bsr_biologics_
registers/bsrbr_rheumatoid_arthritis_register
CORRONA Enquiries via website Yes http://www.corrona.org/
DANBIO Application via website – https://danbio-online.dk/
GISEA – – http://www.gisea.eu/
HRBT – – –
ICEBIO – – –
NOAR Application via website Yes http://www.uea.ac.uk/noar/home
NOR-DMARD – – –
PsART – – –
PsoBEST – – https://www.psobest.de
Reuma Application via website – www.reuma.pt
ROB-FIN – – –
SCQM Application via website – http://www.scqm.ch/
SSATG – – –
SwePsA – – –
UoT Psoriatic Arthritis – – –
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